Exacerbated mitochondrial dynamic abnormalities without evident tau pathology in rapidly progressive Alzheimer's

Yanbin Xiyang1,2, Ju Gao1, Mao Ding1

  • 1Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ, USA.

PubMed
Abstract

Insights

Rapidly progressive Alzheimer's disease (rpAD) shows distinct tau pathology and more severe mitochondrial dysfunction compared to typical Alzheimer's disease (tAD). These differences highlight the need for subtype-specific therapeutic strategies.

Area of Science:

  • Neuroscience
  • Pathology
  • Biochemistry

Background:

  • Rapidly progressive Alzheimer's disease (rpAD) is a subtype of Alzheimer's disease (AD) with accelerated cognitive decline.
  • Both rpAD and typical AD (tAD) feature amyloid plaques and neurofibrillary tangles, but their composition may differ.
  • Mitochondrial dysfunction is implicated in tAD, yet its role in rpAD remains unexplored.

Purpose of the Study:

  • To investigate tau pathology and mitochondrial dysfunction in rpAD compared to tAD.
  • To identify potential pathophysiological differences between AD subtypes.

Main Methods:

  • Immunohistochemical and immunoblot analyses were conducted on postmortem human temporal cortex tissues.
  • Tissues were obtained from patients with tAD, rpAD, and age-matched normal controls.
  • Key regulators of tau phosphorylation and mitochondrial dynamics/bioenergetics were assessed.

Main Results:

  • Typical AD (tAD) showed significant tau phosphorylation (PHF1 epitope), while rpAD exhibited milder phosphorylation, similar to controls.
  • Both tAD and rpAD displayed reduced regulators of mitochondrial dynamics and bioenergetics compared to controls.
  • The reduction in mitochondrial dynamics regulators was more pronounced in rpAD than in tAD.

Conclusions:

  • Tau pathology differs between rpAD and tAD, with rpAD showing less phosphorylation.
  • Mitochondrial dynamics are impaired in both rpAD and tAD, with a greater deficit in rpAD.
  • These findings suggest distinct pathological pathways for AD subtypes, necessitating tailored treatment approaches.